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ABSTRACT
BACKGROUND The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early
invasive strategy with a selective invasive strategy in patients with non–ST-segment elevation acute coronary syndrome
(NSTE-ACS) and an elevated cardiac troponin T. No long-term beneﬁt of an early invasive strategy was found at 1 and 5 years.
OBJECTIVES The aim of this study was to determine the 10-year clinical outcomes of an early invasive strategy versus a
selective invasive strategy in patients with NSTE-ACS and an elevated cardiac troponin T.
METHODS The ICTUS trial was a multicenter, randomized controlled clinical trial that included 1,200 patients with NSTE-ACS
and an elevated cardiac troponin T. Enrollment was from July 2001 to August 2003. We collected 10-year follow-up of death,
myocardial infarction (MI), and revascularization through the Dutch population registry, patient phone calls, general practi-
tioners, and hospital records. The primary outcome was the 10-year composite of death or spontaneous MI. Additional
outcomes included the composite of death or MI, death, MI (spontaneous and procedure-related), and revascularization.
RESULTS Ten-year death or spontaneous MI was not statistically different between the 2 groups (33.8% vs. 29.0%,
hazard ratio [HR]: 1.12; 95% conﬁdence interval [CI]: 0.97 to 1.46; p ¼ 0.11). Revascularization occurred in 82.6% of the
early invasive group and 60.5% in the selective invasive group. There were no differences in additional outcomes, except
for a higher rate of death or MI in the early invasive group compared with the rates for the selective invasive group
(37.6% vs. 30.5%; HR: 1.30; 95% CI: 1.07 to 1.58; p ¼ 0.009), driven by a higher rate of procedure-related MI in the
early invasive group (6.5% vs. 2.4%; HR: 2.82; 95% CI: 1.53 to 5.20; p ¼ 0.001).
CONCLUSIONS In patients with NSTE-ACS and elevated cardiac troponin T levels, an early invasive strategy has no
beneﬁt over a selective invasive strategy in reducing the 10-year composite outcome of death or spontaneous MI, and
a selective invasive strategy may be a viable option in selected patients. (J Am Coll Cardiol 2017;69:1883–93)
© 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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D ifferent treatment strategies areavailable for patients presentingwith non–ST-segment elevation
acute coronary syndromes (NSTE-ACS). In
the ICTUS (Invasive Versus Conservative
Treatment in Unstable Coronary Syndromes)
trial, an early invasive treatment strategy
(also called routine invasive strategy) con-
sisted of intensive antianginal and antith-
rombotic medical treatment aimed at
stabilization and coronary angiography
within 24 to 72 h, and angiography-guided
subsequent appropriate treatment, either by
revascularization or continued optimized
pharmacological therapy. A selective inva-
sive strategy (or ischemia-driven strategy)
also consisted of antianginal and antithrombotic
medical treatment, but with coronary angiography
only in cases of refractory angina or inducible
ischemia by pre-discharge noninvasive stress testing.
The deﬁnitions used in the ICTUS trial predate
the deﬁnitions that are currently used in the
European and American guidelines. Current guide-
lines recommend an early invasive strategy (<24 h)
for high-risk patients, whereas a delayed strategy
(<25 to 72 h) is recommended for intermediate-risk
patients. For low-risk patients either a delayed strat-
egy or an ischemia-driven strategy can be used (1,2).
Importantly, NSTE-ACS patients with an elevated car-
diac troponin T are considered high risk.
Those recommendations are largely based on
multiple randomized clinical trials that have been
included in several meta-analyses (3–6). A patient-
pooled meta-analysis of the FRISC II (Fragmin and
Fast Revascularisation During Instability in Coronary
Artery Disease), ICTUS, and RITA-3 (Third Rando-
mised Intervention Treatment of Angina) trials (FIR)
showed a reduction of long-term rates of cardiovas-
cular death or myocardial infarction (MI) at 5 years,
for patients who underwent an early invasive
strategy (7). In the analysis, the largest risk reduc-
tion was observed in patients with the highest
baseline risk. This reduction in clinical outcomes
was mainly driven by a reduction in nonfatal MI,
whereas a nonsigniﬁcant trend was observed in
cardiovascular death.
Long-term follow-up is important to appreciate the
full clinical impact of such treatment strategies in
NSTE-ACS patients. The ICTUS trial assigned 1,200
NSTE-ACS patients with an elevated cardiac troponin
to either an early invasive or a selective invasive
strategy. After 1 year of follow-up, an early invasive
strategy was not associated with a beneﬁt in death,
MI, or rehospitalization for anginal symptoms despite
an increase in early procedure-related myocardial
infarction (8). At 5-year follow-up, there was no sig-
niﬁcant beneﬁt of an early invasive strategy regard-
less of the patient baseline risk proﬁle (9,10).
Recently, the RITA-3 study showed no difference
between an early invasive or a noninvasive strategy
for all-cause and cardiovascular mortality after 10
years of follow-up, in contrast to the 5-year outcome
that showed a mortality beneﬁt of an early invasive
strategy (3,11). In addition, the 15-year follow-up of
the FRISC-II study was recently published, showing a
signiﬁcant 18-month postponement of the occurrence
of death or next MI and 37 months postponement of
rehospitalization for ischemic heart disease, but
similar mortality with either strategy (12). In this
report we describe the 10-year clinical outcomes of
the ICTUS trial. We report all-cause mortality, car-
diovascular mortality, MI (spontaneous and
procedure-related), and revascularization, and we
assess the impact of baseline risk.
FIGURE 1 Flow Diagram of the ICTUS Trial
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Of a total 1,200 patients, 10-year follow-up was complete for 568 patients in the early
invasive group and 559 patients in the selective invasive group. ICTUS ¼ Invasive Versus
Conservative Treatment in Unstable Coronary Syndromes.
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METHODS
STUDY DESIGN. The original design and methods of
the ICTUS study have been published previously (8).
Between July 2001 and August 2003, we enrolled
1,200 NSTE-ACS patients with an elevated cardiac
troponin T in 42 Dutch hospitals (Online Appendix).
Within 24 h after onset of symptoms, the patients
were randomized to either an early invasive strategy
or a selective invasive strategy.
PATIENTS. Patients ages 18 to 80 years were eligible
if they had all 3 of the following: ongoing chest pain
(>20 min); an elevated cardiac troponin T level
($0.03 g/l); and either ischemic changes as assessed
by electrocardiography (deﬁned as ST-segment
depression or transient ST-segment elevation
exceeding 0.05 mV or T-wave inversion of $0.2 mV in
2 contiguous leads) or a documented history of cor-
onary artery disease (clinical history of MI, percuta-
neous coronary intervention [PCI], and/or coronary
artery bypass graft [CABG]). Patients were excluded
in case of: an ST-segment elevation MI <48 h before
randomization, an indication for reperfusion therapy,
hemodynamic instability or overt congestive heart
failure, and an increased bleeding risk.
TREATMENT STRATEGY. Patients randomized to an
early invasive strategy underwent coronary angiog-
raphy within 24 to 48 h after randomization and the
requirement for revascularization by PCI or CABG was
guided by the ﬁndings of the angiography. Patients
assigned to a selective invasive strategy received
optimal (antianginal) medical treatment. Coronary
angiography was performed in cases of refractory
angina or inducible signs of ischemia during a
mandatory pre-discharge ischemia detection test.
OPTIMIZED MEDICAL THERAPY. All patients
received optimal pharmacological treatment
including aspirin, clopidogrel, enoxaparin, intrave-
nous nitrates, beta-blockers, and intensive lipid-
lowering therapy. The protocol recommended all
PCI be performed with the use of abciximab, given
as bolus of 0.25 mg/kg, followed by an infusion of
0.125 mg/kg/min for 12 h, and started 10 to 60 min
before the ﬁrst balloon inﬂation.
FOLLOW-UP. We collected the patients’ vital status
from the Dutch national population registry at least
10 years after randomization. We contacted all pa-
tients known to be alive at 10 years by telephone to
collect information on rehospitalization for cardiac
reasons. If patients were rehospitalized, we obtained
the discharge letters from the hospitals the patients
were admitted to. If necessary, hospitalization infor-
mation was obtained from their general practitioners.
For deceased patients, we collected clinical event
information and cause of death from their general
practitioners or from hospital records. Patients were
considered lost to follow-up if no contact could be
made with either the patient or the general practi-
tioner. The Medical Ethics Committee of the Aca-
demic Medical Center–University of Amsterdam
approved the long-term follow-up.
OUTCOMES. The main outcome of this study was the
composite of all-cause death and spontaneous MI.
Additional outcomes were the composite of all-cause
death and MI, all-cause death, cardiovascular death,
noncardiovascular death, MI, spontaneous MI,
procedure-related MI, and revascularization by PCI or
CABG. All deaths were considered cardiovascular
unless an unequivocal noncardiovascular cause could
be established. MI was deﬁned as documented
myocardial necrosis either in the setting of myocar-
dial ischemia (spontaneous MI) or in the setting of PCI
or CABG (procedure-related MI) following the
TABLE 1 Baseline Characteristics
Early Invasive
Strategy
(n ¼ 604)
Selective Invasive
Strategy
(n ¼ 596)
Demographics
Age $65, yrs 263 (44) 266 (45)
Body mass index, kg/m2 27  4 27  4
Male 446 (74) 434 (73)
Clinical history
Myocardial infarction 153 (25) 125 (21)
Percutaneous coronary intervention 77 (13) 63 (11)
Coronary artery bypass graft 62 (10) 43 (7)
Risk factors
Current cigarette smoking 244 (40) 248 (42)
Hypertension 226 (37) 240 (40)
Hypercholesterolemia 211 (35) 206 (35)
Diabetes 86 (14) 80 (13)
Family history of coronary disease 263 (44) 241 (40)
Electrocardiographic abnormalities
ST-segment deviation $0.1 mV 284 (49) 290 (51)
Left bundle branch block 8 (1) 6 (1)
Aspirin use at admission 235 (39) 221 (37)
Laboratory assessments
Troponin T, mg/l 0.29 (0.12–0.78) 0.29 (0.13–0.69)
C-reactive protein, mg/l 3.5 (1.7–9.6) 4.3 (1.9–11.4)
Creatinine clearance, ml/min/1.73 m2 85 (68–103) 85 (70–103)
FIR score
Low risk, score 0–4 329 (57) 333 (58)
Intermediate, score 5–8 181 (31) 175 (31)
High, score $9 68 (12) 63 (11)
Values are n (%), mean  SD, or median (interquartile range). C-reactive protein was available in
1,444 patients. Electrocardiogram data were available in 1,149 patients. FIR score could be
calculated for 1,149 patients.
FIR ¼ FRISC II (Fragmin and Fast Revascularisation During Instability in Coronary Artery
Disease)–ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes)–RITA-3
(Third Randomised Intervention Treatment of Angina).
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recommendations of the Consensus Committee for
the deﬁnition of MI (13). All events were adjudicated,
those within the ﬁrst 5 years by a blinded adjudica-
tion committee and later ones by 2 co-authors
(N.P.G.H. and P.D.).
STATISTICAL ANALYSIS. The analyses were by
intention to treat. We calculated the nonparametric
estimator of the cause-speciﬁc cumulative incidence
of revascularization to account for competing risk of
death. We performed a landmark analysis for revas-
cularization with a landmark at 1 year. For all other
outcomes, we used the Kaplan-Meier method to es-
timate cumulative incidence, and Cox proportional
hazards model to obtain hazard ratios (HRs) with
95% conﬁdence intervals (CIs). Follow-up was
censored at 3,655 days or at the last date of known
clinical outcome status for patients with incomplete
follow-up. For endpoints not including all-cause
death, cardiovascular death, or noncardiovascular
death, follow-up was censored at the time of death if
not preceded by the outcome. We performed a strat-
iﬁed analysis according to baseline risk using the FIR
risk score (7). The FIR score is a sum of the following
factors: age (<60 years [þ0], 60 to 64 years [þ1], 65 to
69 years [þ2], 70 to 74 years [þ3], $75 years [þ5]);
diabetes mellitus (þ4); previous MI (þ3); ST-segment
depression (þ2); hypertension (þ1); and body mass
index (<25 [þ1], 25 to <35 [þ0], $35 [þ2]). A multi-
variate predictive model for death or spontaneous MI
was developed with a Cox proportional hazards
model. The model was developed by backward step-
wise elimination from a larger predeﬁned set of
baseline variables including the following: age
$65 years; sex; body mass index; diabetes mellitus;
current smoker at time of enrollment; hypertension;
hypercholesterolemia; family history of coronary
artery disease; history of MI; history of PCI; history
of CABG; aspirin use at admission; C-reactive
protein $10 mg/l; ST-segment depression; ST-
segment elevation; ST-segment deviation; creatinine
clearance #60 ml/min/1.73 m2. We used the Wald test
with a p value of 0.1 for exclusion from the model.
All statistical analyses were performed with SPSS
version 23.0 (SPSS Inc., IBM, Armonk, New York),
except for the calculation of nonparametric estimator
of the cause-speciﬁc cumulative incidence of revas-
cularization and the landmark analysis, for which we
used R version 3.3.0 (R Foundation, Vienna, Austria).
RESULTS
PATIENTS. Of 1,200 patients, 604 patients were
assigned to an early invasive strategy and 596 pa-
tients were assigned to a selective invasive strategy
(Figure 1). The 2 groups showed well-matched base-
line characteristics (Table 1).
The median age was 62 years; approximately 75%
of the patients were male; and 14% had diabetes.
Ischemic electrocardiographic changes were present
in 50% of patients. All patients had elevated cardiac
troponin T levels. The median troponin T level at
FIGURE 2 10-Year Cumulative Incidence of Revascularization Accounted for
Competing Risk of Death and Landmark Analysis of Revascularization With a
Landmark at 1 Year
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(A) Revascularization at 10 years was 83% in the early invasive group and 61% in the
selective invasive group. (B) In a landmark analysis with a landmark at 1 year, there was
no signiﬁcant difference in revascularization rates among the early invasive and selective
invasive groups.
TABLE 2 Cumulative Event Rate by Treatment Strategy
Early
Invasive
(n ¼ 604)
Selective
Invasive
(n ¼ 596) HR (95% CI) p Value
Death or spontaneous MI 199 (33.8) 168 (29.0) 1.12 (0.97–1.46) 0.11
Death or MI 222 (37.6) 177 (30.4) 1.30 (1.07–1.58) 0.009
All-cause death 156 (26.7) 138 (23.7) 1.14 (0.92–1.44) 0.25
Cardiovascular death 97 (17.6) 85 (15.2) 1.15 (0.86–1.54) 0.34
Noncardiovascular death 59 (10.9) 53 (10.0) 1.13 (0.78–1.63) 0.53
MI 106 (18.9) 84 (14.9) 1.30 (0.98–1.73) 0.07
Spontaneous MI 75 (13.8) 72 (12.9) 1.04 (0.75–1.43) 0.82
Procedure-related MI 39 (6.5) 14 (2.4) 2.82 (1.53–5.20) 0.001
Values are number of event outcomes (Kaplan-Meier estimate). The p values are derived from Cox
proportional hazards model.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.
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admission was 0.29 mg/l. Cardiac catheterization was
performed during the initial hospitalization in 98% of
patients in the early invasive group and 53% in the
selective invasive group. Within 1 year, 79% of the
patients in the early invasive group had undergone
revascularization compared with 54% in the selective
invasive group. When we accounted for competing
risk of death, the 10-year revascularization rate was
83% in the early invasive group and 61% in the se-
lective invasive group (Figure 2A). There was no dif-
ference in revascularization from 1 year to 10 years of
follow-up (p ¼ 0.61) (Figure 2B).
OUTCOMES. Vital status at 10 years was known for
1,152 patients (96.0%) and was equally distributed
between both groups (Figure 1). Clinical outcome
status (MI and revascularization) at 10 years was
known for 1,171 patients (97.6%), 594 patients (98.3%)
in the early invasive group and 577 patients (96.8%)
in the selective invasive group. Table 2 displays the
10-year cumulative event rates and HR of the main
composite and individual outcomes. The 10-year
composite outcome of death or spontaneous MI was
33.8% for the early invasive group and 29.0% for
the selective invasive group (Central Illustration)
(HR: 1.12; 95% CI: 0.97 to 1.46; p ¼ 0.11) and 37.6%
versus 30.4% (HR: 1.30; 95% CI: 1.07 to 1.58;
p ¼ 0.009) for death or MI, respectively.
Figure 3 shows the Kaplan-Meier curves for the
other additional outcomes. There was no difference in
all-cause death for early invasive strategy (26.6%)
versus selective invasive strategy (23.7%) (HR: 1.14;
95% CI: 0.91 to 1.44; p ¼ 0.25) (Table 2, Figure 3A) or for
cardiovascular death (17.6% vs. 15.2%, respectively;
HR: 1.15; 95% CI: 0.86 to 1.54; p ¼ 0.34) (Table 2,
Figure 3C). Additionally, MI in the early invasive group
was 18.9% versus 14.9% in the selective invasive group
(HR: 1.30; 95% CI: 0.98 to 1.73; p ¼ 0.07) (Table 2,
Figure 3B). This nonsigniﬁcant difference in MI was
mainly driven by a higher rate of procedure-related
MI: 6.5% versus 2.4% for early invasive and selective
invasive strategies, respectively (HR: 2.82; 95% CI: 1.53
to 5.20; p ¼ 0.001), as the 10-year rate of spontaneous
MI was similar in both groups (13.8% vs. 12.9%
respectively; HR: 1.04; 95% CI: 0.75 to 1.43; p ¼ 0.82).
RISK STRATIFICATION. Figure 4 displays the Kaplan-
Meier estimate curves for death or spontaneous MI
stratiﬁed by FIR score. Therewas no beneﬁt for an early
invasive strategy regardless of the baseline risk: 1)
for low risk, HR¼0.95 (95%CI: 0.67 to 1.34; p¼0.76); 2)
for intermediate risk, HR ¼ 1.40 (95% CI: 0.99 to 1.97;
p ¼ 0.054); and 3) for high risk, HR ¼ 1.07 (95% CI: 0.69
to 1.67; p ¼ 0.76). Looking at both risk score (FIR) and
treatment strategy, we could not demonstrate an
interaction of sex with outcomes.
CENTRAL ILLUSTRATION Early Invasive Strategy Versus a Selective Invasive Strategy in High-Risk Patients:
10-Year Clinical Outcomes
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Kaplan-Meier estimates of the cumulative rate of the composite outcomes of death or spontaneous myocardial infarction (MI) (A) and death or MI (B). In patients with
non–ST-segment elevation acute coronary syndrome and an elevated troponin level, an early invasive strategy did not reduce the outcomes of death or spontaneous
MI and death or MI at 10 years. Hazard ratios (HRs) and p values were obtained with Cox proportional hazards models. CI ¼ conﬁdence interval.
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MULLTIVARIATE MODELS. Table 3 shows baseline
characteristics independently associated with 10-year
death or spontaneous MI. In the multivariate model,
there was no difference between the early invasive
and selective invasive strategy with regard to the
10-year risk of death or spontaneous MI (HR: 1.20;
95% CI: 0.97 to 1.48; p ¼ 0.096).
DISCUSSION
In this study, we report the 10-year clinical outcomes
of the ICTUS study. Our results show that, in patients
with NSTE-ACS with elevated cardiac troponin T
levels, there was no beneﬁt associated with an early
invasive strategy in reducing death or spontaneous
MI after 10 years of follow-up. In addition, we did not
observe differences in rates of death or spontaneous
MI after risk stratiﬁcation with the FIR score. No late
effects were observed, with comparable increments
for death or MI in both treatment groups up to 10-year
follow-up. Although more procedure-related MI
occurred in the early invasive group, there was no
signiﬁcant difference in mortality at 10 years. The
current result conﬁrms and extends the results of
previous studies, with one-third of patients enduring
death or spontaneous MI within 10 years despite
treatment. These ﬁndings are in contrast to the re-
sults of the long-term outcome of the FRISC-II and
RITA-3 studies, where a beneﬁt of an early invasive
strategy was shown.
CONTEXT AND INTERPRETATION OF THE CURRENT
RESULTS. There may be many reasons for the dif-
ferences observed in the ICTUS trials when compared
with the FRISC-II and RITA-3 studies. The trials
enrolled patients in different time periods, and there
were differences in clinical practice. Compared with
the RITA-3 and FRISC-II trials, the ICTUS trial was the
most contemporary and included the use of stents,
glycoprotein IIb/IIIa inhibitors during PCI, long-term
FIGURE 3 Kaplan-Meier Estimates of the Cumulative Rate of Death, MI, Cardiovascular Death, and Noncardiovascular Death
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(dual) antiplatelet agents, and high-dose statin
treatment.
Perhaps the most important difference among the 3
trials was the timing and intensity of revasculariza-
tion (Figure 5). In the ICTUS trial, in the early invasive
strategy as per protocol, 97% of patients underwent
coronary angiography within 48 h and 98% during
hospitalization (8). Coronary angiography during
hospitalization was 96% in both early invasive groups
of RITA-3 and FRISC-II, and by design, was to be
performed <72 h from randomization and <7 days
from admission for the index event, respectively
(14,15). More importantly, coronary angiography
during hospitalization in the noninvasive groups of
FRISC-II and RITA-3 was only 7% and 16%, respec-
tively, compared with 53% of patients in the selective
invasive group in ICTUS, which better reﬂects
contemporary practice (8,14,15). All patients in ICTUS
were troponin positive, making the presence of an
ACS more likely. Furthermore, after diagnostic coro-
nary angiography, subsequent revascularization was
more frequent in the ICTUS trial. Revascularization
during hospitalization was 76% in the early invasive
group and 40% in selective invasive group compared
with 76% in the early invasive group versus 14% in
the noninvasive group of FRISC-II and 44% versus
10% in RITA-3 (8,14,15).
Meta-analyses have shown a mortality beneﬁt with
an early invasive strategy at 2 years when combining
data from randomized trials (5,16). In ICTUS, an ab-
solute 22% difference in revascularization between
the early invasive and the selective invasive group
was sustained until 10 years, with mortality showing
no difference at 1-, 5-, and 10-year follow-up. In
FRISC-II, a signiﬁcant difference in mortality was
observed at 2 years, which dissipated at 5-year and
15-year follow-ups (4,12). In the RITA-3 study, there
was no difference in mortality at 2-year follow-up.
A signiﬁcant difference in mortality was observed at
5 years, which no longer existed at 10-year follow-up
(3,11). We are unaware of a plausible pathophysio-
logical mechanism or change in clinical practice over
time that may explain these observations. Therefore,
considering the long-term observations of all 3 strat-
egy trials, one may assume that any observed differ-
ence in mortality is the result of a play of chance.
In summary, although the 3 individual trials may not
be statistically powered to detect a difference in
FIGURE 4 Kaplan-Meier Estimates of the Cumulative Rate of the Composite Outcome of Death or Spontaneous MI Stratiﬁed and Divided
in 3 Groups
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mortality, the long-term ($10 years) results found in
the 3 studies suggest that, compared with a selective
invasive strategy, an early invasive strategy is
not associated with a long-term mortality beneﬁt,
even in NSTE-ACS patients with an elevated cardiac
troponin.
Concerning the incidence of MI, the long-term re-
sults varied among the 3 strategy trials. Our current
results show there is no beneﬁt associated with an
early invasive strategy in reducing death or MI at 10
years, and our results are consistent with the earlier
results from the ICTUS study (8–10). At 1 and 5 years,
an early invasive strategy was not associated with a
reduction in the composite of death or MI. Nor was
there is difference in the 2 individual endpoints. In
contrast to our results, the 5-year composite of death
or MI in RITA-3 was higher in the noninvasive group
(20.0%) compared with the early invasive group
(16.6%; p ¼ 0.044) (3). Yet, MI as an individual
endpoint did not differ between the 2 groups at 5
years (early invasive: 6.8% vs. 8.3%; p ¼ 0.22). In
FRISC-II, death or MI at 5 years was signiﬁcantly
higher in the noninvasive group (24.5% vs. 19.9%;
p ¼ 0.009) and was mainly driven by a higher number
of MI in the noninvasive group (17.7%) compared with
the early invasive group (12.9%; p ¼ 0.002) (4).
Looking at all events, not just the ﬁrst event, this
result persisted at 15 years of follow-up in FRISC-II.
In this study, an early invasive strategy was associ-
ated with a postponement of death or new MI by 18
months and death or next readmission for ischemic
heart disease by 37 months. This was mainly driven
by a higher rate of MI or readmission in the nonin-
vasive group during the ﬁrst 3 to 4 years of the study,
with the event curves running parallel thereafter (12).
Again, the difference in early revascularization be-
tween the early invasive and the noninvasive treat-
ment arm in FRISC-II was profound, with unplanned
revascularization occurring 30% more often in the
noninvasive group during the ﬁrst 3 to 4 years. Thus,
the more frequent occurrence of spontaneous MI in
the noninvasive group in the ﬁrst 3 years in FRISC-II
over time, parallels a low percentage of early revas-
cularization followed by more frequent unplanned
revascularization at a later time when compared with
the early invasive group. Current European and
American NSTE-ACS guidelines recommend an early
invasive strategy for troponin-positive patients, with
coronary angiography being done preferably within
24 h (1,2). Yet, in the long-term results of FIR there
was no mortality beneﬁt associated with an early
invasive strategy. Moreover, we could not show a
reduction in MI at 10-year follow-up, provided there
was a revascularization rate of 61% in the selective
invasive group at 10 years (with an absolute differ-
ence in revascularization of 22%). Taken together,
when balancing the risks and beneﬁts of angiography
and revascularization, we conclude that a selective
invasive strategy may be a viable option in selected
patients.
FUTURE PERSPECTIVES. We acknowledge several
important developments in diagnostic and thera-
peutic armamentarium for NSTE-ACS patients over
the past years. First, the high-sensitivity troponin
assay (hs-cTn) is now widely available. The intro-
duction of hs-cTn has improved the rule-out process
in NSTE-ACS patients with a normal hs-cTn (17). Since
its introduction, hs-cTn also has markedly changed
the troponin-positive NSTE-ACS population; a recent
study demonstrated an increase of troponin-positive
NSTE-ACS (or non–ST-segment elevation MI) and a
decrease in unstable angina diagnoses at discharge
TABLE 3 Multivariate Predictors of Death or Spontaneous MI at 10-Year
Follow-Up
Number
of Events % HR (95% CI) p Value
Allocated treatment strategy 0.097
Selective invasive 168/596 28.2 1.00
Early invasive 199/604 32.9 1.20 (0.97–1.48)
Age $65 yrs <0.001
No 132/671 19.7 1.00
Yes 235/529 44.4 2.25 (1.77–2.86)
Diabetes mellitus <0.001
No 283/1,034 27.4 1.00
Yes 84/166 50.6 1.62 (1.24–2.11)
Current smoker 0.094
No 228/708 32.2 1.00
Yes 139/492 28.3 1.21 (0.97–1.52)
Hypercholesterolemia 0.009
No 205/783 26.2 1.00
Yes 162/417 38.8 1.36 (1.08–1.72)
History of MI 0.007
No 239/922 25.9 1.00
Yes 128/278 46.0 1.43 (1.10–1.86)
Aspirin use prior to admission 0.052
No 174/744 23.4 1.00
Yes 193/456 42.2 1.29 (0.99–1.66)
C-reactive protein $10 mg/l 0.001
No 252/906 27.8 1.00
Yes 115/294 39.1 1.49 (1.20–1.87)
Cumulative ST-segment deviation $0.1 mV 0.065
No 303/1,012 29.9 1.00
Yes 42/137 30.7 1.22 (0.99–1.51)
Creatinine clearance <60 mmol/l <0.001
No 299/1,082 27.6 1.00
Yes 68/117 58.1 1.78 (1.32–2.39)
Abbreviations as in Table 2.
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(18). Subsequently, a rise or fall in cardiac troponin
has been indicated as a high-risk feature, mandating
an invasive strategy by the most recent treatment
guidelines. Therefore, more patients who were pre-
viously diagnosed with unstable angina now have an
indication for early coronary angiography. Patients
with minor elevations measured with hs-cTn, who are
at the lower end of the risk spectrum, have not been
included in any the strategy trials.
Second, pharmacological and invasive treatment
options, used at the time of enrollment of the
study, have been developed further. For example,
several trials with novel P2Y12 inhibitors have
shown beneﬁt over clopidogrel in reducing death,
MI, and stroke, including patients with an intended
noninvasive management (19–21). The use of radial
approach is more prevalent and has been shown to
reduce major bleeding in NSTE-ACS patients,
and stent technology has improved with the
introduction of latest generation drug-eluting
stents (22,23).
Finally, we emphasize the importance of secondary
prevention by means of optimized medical treatment,
lifestyle changes, and smoking cessation, as recom-
mended by international guidelines (1,2). As all these
new developments affect both an early invasive
approach and a more selective invasive approach, a
future study is warranted.
STUDY LIMITATIONS. First, we collected our follow-
up information through patient phone calls, general
practitioners, hospital records, and the national pop-
ulation registry. Unreported hospital admissions or
patients who were lost-to-follow-up may lead to an
underestimation of event rates. Second, routine serial
measurement of cardiac biomarkers after PCI was not
part of clinical practice during long-term follow-up and
some procedure-related MI without clinical symptoms
FIGURE 5 Catheterization and Revascularization Rates in FRISC-II, RITA-3, and ICTUS
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may have been missed. Third, the results of this study
reﬂect clinical practice in theDutch health care system.
The Netherlands is a small, densely populated country
with many heart centers, adequate capacity for PCI or
CABG, and well-organized primary care. Fourth, mean
age of the patients in our study was 62 years with
relatively few patients older than 80 years, making a
comparison with the recently published After Eighty
study difﬁcult (24). Finally, although the quality of
secondary prevention including medical treatment
was likely to be high, this was not prospectively
recorded during the 10-year follow-up.
CONCLUSIONS
Our results show that, in patients with NSTE-ACS
with elevated cardiac troponin T levels, an early
invasive strategy has no beneﬁt in reducing the 10-
year composite and individual outcomes of death or
spontaneous MI. Additionally, rates of the composite
of death or spontaneous MI did not differ after risk
stratiﬁcation for baseline risk with the FIR score.
When balancing the risks and beneﬁts of angiography
and revascularization, we believe that a selective
invasive strategy may be a viable option in selected
patients. Future randomized controlled trials reﬂect-
ing present-day clinical practice for NSTE-ACS pa-
tients, are warranted.
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